Progress on antitumor effects of zoledronic acid in breast cancer

Abstract

Abstract:As the thirdgeneration bisphosphonate, zoledronic acid (ZOL) has been widely used for the treatment of skeletalrelated events in breast cancer. Previous studies have demonstrated that ZOL has antitumor activitie in breast cancer. ZOL can induce direct and indirect antitumor activities through inducing apoptosis, inhibiting the proliferation, adhesion and invasion formation of bone microenvironment which is conducive to tumor growth, besides inhibiting angiogensis and modulating immune response. Also evidences of synergistic antitumor effects are found when ZOL combines with radiotherapy and chemotherapy, endocrine, and targeted drugs. The observed improvement in antitumor effects by using combination therapy with ZOL in breast cancer is currently being verified through additional clinical trials.

Key words:Antineoplastic agents,Breast neoplasms,Zoledronic acid

CHEN Chen, SUN Wei-Li, CHEN Jia, HUO Jie-Ge. Progress on antitumor effects of zoledronic acid in breast cancer[J]. Journal of International Oncology, 2014, 41(3): 196-199.

References

［1］ Insalaco L, Di Gaudio F, Terrasi M, et al. Analysis of molecular mechanisms and antitumoural effects of zoledronic acid in breast cancer cells［J］. J Cell Mol Med, 2012, 16(9):21862195. ［2］何杰文, 范华, 梁桂才. 唑来膦酸的临床应用［J］. 中国现代药物应用, 2012, 6(18):9293. ［3］ Brown HK, Holen I. Antitumour effects of bisphosphonateswhat have we learned from in vivo models?［J］. Curr Cancer Drug Targets, 2009, 9(7):807823. ［4］ Rikknen J, Mnkknen H, Aurioa S, et,al. Mevalonate pathway intermediates downregulate zoledronic acidinduced isopentenyl pyrophosphate ATP analog formation in human breast cancer cells［J］. Biochem pharmacol, 2010, 79（5）：773783. ［5］马宇光. 唑来膦酸治疗乳腺癌的新机制: BK_(Ca)通道的调控作用［DI］.西安：第四军医大学，2012. ［6］王增，卢红阳，翁琳. 唑来膦酸抗肿瘤作用的临床研究进展［J］.中国临床药理学与治疗学， 2011, 16(8)：945950. ［7］杨昀，蒋永来，季国忠. 基质金属蛋白酶与大肠癌侵袭和转移关系的研究进展［J］. 医学研究生学报, 2010, 23(7):771773. ［8］ Dedes PG, Gialeli Ch, Tsonis AI, et,al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid［J］. Biochim Biophys Acta, 2012, 1820(12):19261939. ［9］ Perifanis V, Vyzantiadis T, Tziomalos K, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with betathalassaemia［J］. Ann Hematol, 2007, 86(1):2330. ［10］ Khosravi Shahi P, Fernández Pineda I. Tumoral angiogenesis: review of the literature［J］. Cancer Invest, 2008, 26(1):104108. ［11］黄海. 唑来膦酸对乳腺癌细胞小鼠移植瘤模型抑制效果及机制探讨［J］. 健康必读, 2011， (6)：264265. ［12］ Thompson K, Roelofs AJ, Jauhiainen M, et al. Activation of γδ T cells by bisphosphonates［J］. Adv Exp Med Biol， 2010， 658:1120. ［13］ Su X, Zhang L, Jin L, et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the antitumor effects of cytokineinduced killer cells［J］.J Clin Inmunol, 2010, 30(5):766774. ［14］于卫卫. 唑来膦酸与紫杉醇协同抑制恶性肿瘤细胞增殖及诱导凋亡的分子机制研究［DI］.天津：天津医科大学,2011. ［15］ Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response:exploratory evidence for direct antitumour activity in breast cancer［J］. Br J Cancer, 2010,102(7):10991105. ［16］ Gnant M， Eidtmann H. The antitumor effect of bisphosphonates ABCSG12,ZOFAST and more［J］. Grit Rev Oncol Hematol, 2010, 74Suppl 1:S26. ［17］ Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36month results of the ZOFAST study［J］. Ann Oncol, 2010, 21(11):21882194. ［18］徐亮，郝晓甍，张敏，等. 唑来膦酸预防芳香化酶抑制剂引起骨丢失的临床研究［J］. 中国肿瘤临床， 2010, 37（6）：392394.

[1]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[14]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96.